← Back to Search

Other

Alcohol-related liver disease and AUD, MELD-NA less than 20 for Alcoholic Liver Disease

Phase 2
Waitlist Available
Led By Douglas A Simonetto
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

Study Summary

This trial found that acamprosate is a safe and effective treatment for alcohol dependence in individuals with liver disease.

Eligible Conditions
  • Alcoholic Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Event
Secondary outcome measures
Change in Alcohol Craving

Trial Design

2Treatment groups
Experimental Treatment
Group I: Alcohol-related liver disease and AUD, MELD-NA more than 20Experimental Treatment1 Intervention
The second 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score more than 20.
Group II: Alcohol-related liver disease and AUD, MELD-NA less than 20Experimental Treatment1 Intervention
The first 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score less than 20.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acomprosate
2020
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,210 Previous Clinical Trials
3,766,961 Total Patients Enrolled
Douglas A SimonettoPrincipal InvestigatorMayo Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Acamprosate Safe to Use in Individuals With Liver Disease.
Douglas (Doug) A. Simonetto 2020. "Acamprosate Safe to Use in Individuals With Liver Disease.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04287920.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top